Recombinant human VEGF189 protein (ab106307)
Key features and details
- Expression system: Escherichia coli
- Purity: > 98% SDS-PAGE
- Endotoxin level: < 0.100 Eu/µg
- Active: Yes
- Suitable for: Functional Studies, SDS-PAGE
製品の詳細
-
製品名
Recombinant human VEGF189 protein -
生理活性
Measured by the stimulation of cell proliferation in human umbilical vein endothelial cells in the range of 2-20 ng/ml.
-
精製度
> 98 % SDS-PAGE.
Gel filtration, purification via Uno S6 -
エンドトキシン・レベル
< 0.100 Eu/µg -
発現系
Escherichia coli -
アクセッション番号
-
タンパク質長
Full length protein -
Animal free
No -
由来
Recombinant -
-
生物種
Human -
配列
APMAEGGGQNHHEVVKFMDVYQRSYCHPIETLVDIFQEYPDEIEYIFKPS CVPLMRCGGCCNDEGLECVPTEESNITMQIMRIKPHQGQHIGEMSFLQHN KCECRPKKDRARQEKKSVRGKGKGQKRKRKKSRYKSWSVPCGPCSERRKH LFVQDPQTCKCSCKNTDSRCKARQLELNERTCRCDKPRR -
予測される分子量
42 kDa -
領域
27 to 232 -
配列の追加情報
Mature protein without signal peptide.
-
関連製品
-
Related Products
特性
Our Abpromise guarantee covers the use of ab106307 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
アプリケーション
Functional Studies
SDS-PAGE
-
製品の状態
Lyophilized -
備考
Molecular weight: ~42 kDa (Dimer)
-
Concentration information loading...
前処理および保存
-
保存方法および安定性
Shipped at 4°C. The lyophilized protein is stable for a few weeks at room temperature. Store at -20°C long term.
Constituent: 0.3% Acetic acid
This product is an active protein and may elicit a biological response in vivo, handle with caution.
-
再構成Should be reconstituted in PBS or medium containing at least 0.1% human or bovine serum albumin to a concentration not lower than 50 µg/ml.
関連情報
-
別名
- MGC70609
- MVCD1
- Vascular endothelial growth factor A
see all -
機能
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. -
組織特異性
Isoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed. -
関連疾患
Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. -
配列類似性
Belongs to the PDGF/VEGF growth factor family. -
細胞内局在
Secreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin. - Information by UniProt
画像
-
VEGF-A Sandwich-ELISA using VEGF189 as standard. Mouse anti-human VEGF-A was used as capture antibody, Biotinylated mouse anti-human VEGF-A was used for detection.
-
SDS-PAGE analysis of recombinant human VEGF-A isoforms produced in E. coli. Samples were loaded under non-reducing conditions in 15% SDS-polyacrylamide gel and stained with Silver stain.
-
VEGF189-induced proliferation of primary human dermal lymphatic endothelial cells (HDLEC). HDLECs were stimulated with increasing amounts of recombinant human VEGF189.
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (2)
ab106307 は 2 報の論文で使用されています。
- Patel N et al. Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumab. EJNMMI Res 7:49 (2017). WB . PubMed: 28560583
- Hettema W et al. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects. Expert Opin Investig Drugs 26:889-896 (2017). PubMed: 28651442